Perrigo launches generic Zaditor
This article was originally published in The Tan Sheet
Executive Summary
Perrigo ships its generic of Novartis Pharmaceuticals' Zaditor, a ketotifen fumarate ophthalmic solution, .025 percent, the Allegan, Mich.-based private labeler says in a March 15 release. Perrigo CEO Joseph Papa said the firm is "excited to launch into a new adjacent OTC category, ophthalmics." Zaditor is a solution used to temporarily prevent allergic conjunctivitis. Wolters Kluwer data estimates the annual sales of Zaditor in the last 12 months reached $15 million, Perrigo said. Competition in the eye-care market increased with the recent launch of Johnson & Johnson/McNeil's Zyrtec Allergy Eye Relief Drops and Schering-Plough's Claritin Eye, which also contain ketotifen fumarate as the active ingredient (1"The Tan Sheet" Jan. 11, 2010)
You may also be interested in...
Zyrtec and Claritin Eye Drops Use Different Tactics In Head To Head Fight
Thanks to a multi-media blitz, McNeil's Zyrtec Allergy Eye Relief Drops secured nearly twice the market share as a Claritin product from Schering-Plough with the same active drug that launched at the same time in summer 2009
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.